PBLA
Income statement / Annual
Last year (2023), Panbela Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Panbela Therapeutics, Inc.'s net income was -$25.26 M.
See Panbela Therapeutics, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.36 M
|
| Cost of Revenue |
$25.65 M |
$35.73 M |
$10.01 M |
$5.75 M |
$4.32 M |
$3.89 M |
$6.02 M |
$5.17 M |
$5.44 M |
$595,152.00 |
| Gross Profit |
-$25.65 M |
-$35.73 M |
-$10.01 M |
-$5.75 M |
-$4.32 M |
-$3.89 M |
-$6.02 M |
-$5.17 M |
-$5.44 M |
$761,843.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0.56 |
| Research and Development
Expenses |
$20.61 M
|
$28.05 M
|
$5.42 M
|
$2.51 M
|
$2.35 M
|
$1.78 M
|
$2.59 M
|
$2.50 M
|
$2.85 M
|
$2,366.00
|
| General & Administrative
Expenses |
$5.03 M
|
$6.04 M
|
$4.59 M
|
$3.25 M
|
$1.97 M
|
$2.11 M
|
$3.42 M
|
$2.66 M
|
$2.81 M
|
$837,241.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$217,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.03 M
|
$6.04 M
|
$4.59 M
|
$3.25 M
|
$1.97 M
|
$2.11 M
|
$3.42 M
|
$2.66 M
|
$2.59 M
|
$837,241.00
|
| Other Expenses |
$0.00 |
-$682,000.00 |
-$602,000.00 |
$605,000.00 |
-$99,000.00 |
-$508,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$25.65 M |
$34.09 M |
$10.01 M |
$5.75 M |
$4.32 M |
$3.84 M |
$6.02 M |
$5.17 M |
$5.44 M |
$837,241.00 |
| Cost And Expenses |
$51.29 M |
$34.09 M |
$10.01 M |
$5.75 M |
$4.32 M |
$3.84 M |
$6.02 M |
$5.17 M |
$5.44 M |
$1.43 M |
| Interest Income |
$123,000.00 |
$14,000.00 |
$1,000.00 |
$17.00 |
$2,194.00 |
$0.00 |
$1,000.00 |
$2,000.00 |
$8,000.00 |
$4,002.00 |
| Interest Expense |
-$317,000.00 |
$288,000.00 |
$11,000.00 |
$17,000.00 |
$2.19 M |
$1.81 M |
$1.62 M |
$180,000.00 |
$183,000.00 |
$35,527.00 |
| Depreciation &
Amortization |
$0.00
|
$16,356.00
|
$10,010.00
|
$5,754.00
|
$4,322.00
|
$3,891.00
|
$6,016.00
|
$5,168.00
|
$8,000.00
|
$9,578.00
|
| EBITDA |
-$51.29 M
|
-$34.76 M
|
-$10.61 M
|
-$5.15 M
|
-$4.42 M
|
-$1.76 M
|
-$6.02 M
|
-$5.17 M
|
-$5.12 M
|
-$75,398.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-0.05 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.06
|
| Total Other
Income/Expenses Net |
$25.85 M
|
-$956,000.00
|
-$613,000.00
|
$691,000.00
|
-$2.29 M
|
-$2.27 M
|
-$4.89 M
|
-$285,000.00
|
-$564,000.00
|
-$31,525.00
|
| Income Before Tax |
-$25.45 M |
-$35.05 M |
-$10.62 M |
-$5.06 M |
-$6.62 M |
-$6.16 M |
-$10.91 M |
-$5.45 M |
-$5.68 M |
-$106,923.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-0.08
|
| Income Tax Expense |
-$186,000.00 |
-$116,000.00 |
-$488,000.00 |
-$295,000.00 |
-$415,000.00 |
-$254,000.00 |
-$536,000.00 |
-$341,000.00 |
-$756,000.00 |
$121.00 |
| Net Income |
-$25.26 M |
-$34.93 M |
-$10.14 M |
-$4.77 M |
-$6.20 M |
-$5.91 M |
-$10.37 M |
-$5.11 M |
-$4.93 M |
-$107,044.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-0.08 |
| EPS |
-232429.55 |
-40748.57 |
-20773.7 |
-14798.1 |
-26103.83 |
-1519.95 |
-3491.75 |
-1974.51 |
-4203.92 |
-892.03 |
| EPS Diluted |
-232429.55 |
-40748.57 |
-20773.7 |
-14798.1 |
-26103.83 |
-1519.95 |
-3491.75 |
-1974.51 |
-4203.92 |
-892.03 |
| Weighted Average Shares
Out |
$108.69
|
$857.28
|
$487.88
|
$322.20
|
$237.51
|
$3,885.00
|
$2,971.00
|
$2,589.00
|
$1,172.00
|
$120.00
|
| Weighted Average Shares
Out Diluted |
$108.69
|
$857.28
|
$487.88
|
$322.20
|
$237.51
|
$3,885.00
|
$2,971.00
|
$2,589.00
|
$1,172.00
|
$120.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
